EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Robust use of phenotypic heterogeneity at drug target genes for mechanistic insights: Application of cis ‐multivariable Mendelian randomization to GLP1R gene region

Ashish Patel iD, Dipender Gill, Dmitry Shungin, Christos S Mantzoros, Lotte Bjerre Knudsen, Jack Bowden, Stephen Burgess iD

Genetic Epidemiology · 2024-06 · 48 (4) · 151-163

DOI: 10.1002/gepi.22551 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genetic Epidemiology, online erschienen am 20.02.2024. Verfasst von Ashish Patel und 6 weiteren Autor:innen. Beteiligte Einrichtung: MRC Biostatistics Unit, University of Cambridge, Cambridge, UK. Hauptthemen laut MEDLINE: Mendelian Randomization Analysis, Glucagon-Like Peptide-1 Receptor, Diabetes Mellitus, Type 2, Coronary Artery Disease. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health Research Cambridge Biomedical Research Centre, Wellcome Trust and Royal Society, Department of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Phenotypic heterogeneity at genomic loci encoding drug targets can be exploited by multivariable Mendelian randomization to provide insight into the pathways by which pharmacological interventions may affect disease risk. However, statistical inference in such investigations may be poor if overdispersion heterogeneity in measured genetic associations is unaccounted for. In this work, we first develop conditional F statistics for dimension‐reduced genetic associations that enable more accurate measurement of phenotypic heterogeneity. We then develop a novel extension for two‐sample multivariable Mendelian randomization that accounts for overdispersion heterogeneity in dimension‐reduced genetic associations. Our empirical focus is to use genetic variants in the GLP1R gene region to understand the mechanism by which GLP1R agonism affects coronary artery disease (CAD) risk. Colocalization analyses indicate that distinct variants in the GLP1R gene region are associated with body mass index and type 2 diabetes (T2D). Multivariable Mendelian randomization analyses that were corrected for overdispersion heterogeneity suggest that bodyweight lowering rather than T2D liability lowering effects of GLP1R agonism are more likely contributing to reduced CAD risk. Tissue‐specific analyses prioritized brain tissue as the most likely to be relevant for CAD risk, of the tissues considered. We hope the multivariable Mendelian randomization approach illustrated here is widely applicable to better understand mechanisms linking drug targets to diseases outcomes, and hence to guide drug development efforts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mendelian Randomization AnalysisGlucagon-Like Peptide-1 ReceptorDiabetes Mellitus, Type 2Coronary Artery DiseasePhenotypeBody Mass IndexHumansPolymorphism, Single NucleotideGenetic Predisposition to Disease

Stichwörter der Autor:innen

GLP1R agonistsdrug target Mendelian randomizationoverdispersion heterogeneityphenotypic heterogeneity

Substanzen

Glucagon-Like Peptide-1 Receptor

Autor:innen und Institutionen

  • MRC Biostatistics Unit, University of Cambridge, Cambridge, UK.
  • Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
  • Human Genetics Centre of Excellence, AI and Digital Research, Novo Nordisk, Bagsværd, Denmark.
  • Department of Internal Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Internal Medicine, Boston VA Healthcare System, Harvard Medical School, Boston, Massachusetts, USA.
  • Chief Scientific Advisor Office, Research and Early Development, Novo Nordisk, Bagsværd, Denmark.

ORCID-Profile: Ashish Patel, Stephen Burgess

Förderung

  • National Institute for Health Research Cambridge Biomedical Research Centre
  • Wellcome Trust and Royal Society
  • Department of Health
  • Wellcome Trust
  • United Kingdom Research and Innovation Medical Research Council
  • Medical Research Council

Zitieren

APA

Patel, A., Gill, D., Shungin, D., Mantzoros, C. S., Knudsen, L. B., Bowden, J., & Burgess, S. (2024). Robust use of phenotypic heterogeneity at drug target genes for mechanistic insights: Application of cis ‐multivariable Mendelian randomization to GLP1R gene region. Genetic Epidemiology, 48(4), 151-163. https://doi.org/10.1002/gepi.22551

Vancouver

Patel A, Gill D, Shungin D, Mantzoros CS, Knudsen LB, Bowden J, et al. Robust use of phenotypic heterogeneity at drug target genes for mechanistic insights: Application of cis ‐multivariable Mendelian randomization to GLP1R gene region. Genetic Epidemiology. 2024;48(4):151-163. doi:10.1002/gepi.22551

BibTeX
@article{Patel2024,
  author = {Patel, Ashish and Gill, Dipender and Shungin, Dmitry and Mantzoros, Christos S and Knudsen, Lotte Bjerre and Bowden, Jack and Burgess, Stephen},
  title = {Robust use of phenotypic heterogeneity at drug target genes for mechanistic insights: Application of cis ‐multivariable Mendelian randomization to GLP1R gene region},
  journal = {Genetic Epidemiology},
  year = {2024},
  volume = {48},
  number = {4},
  pages = {151--163},
  doi = {10.1002/gepi.22551}
}
Kostenlos starten →